Relay Therapeutics prices $316M public offering; underwriters exercise overallotment

Relay Therapeutics, Inc.

Entered underwriting agreement for 22,916,667 shares at $12.00/sh; full exercise of 3,437,500 overallotment option.
Net proceeds estimated at ~$296.8M after underwriting discounts and expenses; total shares offered 26,354,167.
Offering expected to close May 22, 2026, led by Jefferies LLC and TD Securities (USA) LLC.
Shares sold under existing shelf registration statement; significant dilution to existing shareholders.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Relay Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters valued at approximately $296.8 million (effective 2026-05-20).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters
Value: approximately $296.8 million
Effective: 2026-05-20

Exact text from the filing

On May 20, 2026, Relay Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 22,916,667 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $12.00 per share.

View on SEC.gov

Browse all material agreements →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-234862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.